miR‑181b‑p53 negative feedback axis regulates osteosarcoma cell proliferation and invasion

Wan,Jun; Long,Feng; Zhang,Can; Liu,Yupeng

doi:10.3892/ijmm.2020.4558

miR‑181b‑p53 negative feedback axis regulates osteosarcoma cell proliferation and invasion

Authors:
- Jun Wan
- Feng Long
- Can Zhang
- Yupeng Liu
View Affiliations

Affiliations: Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: March 31, 2020 https://doi.org/10.3892/ijmm.2020.4558
Pages: 1803-1813
Copyright: © Wan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is one of the most common malignant tumors in young adults and has a high distant metastasis rate. The p53 protein, a potent prognostic biomarker for patients with OS, is altered in ~50% of OS cases. p53 was reported to exert its effects through regulating the transcription of microRNAs (miRNAs/miRs) and other genes. In the present study, the expression of miR‑181b, a critical OS oncomiR, was shown to be significantly upregulated whereas p53 expression was downregulated within OS tissues and cells; in tissue samples, miR‑181b and p53 were negatively correlated. p53 inhibited the transcription of miR‑181b via targeting its promoter region, whereas miR‑181b bound the TP53 3'‑untranslated region (UTR) to inhibit p53 expression. miR‑181b silencing considerably increased p53, p21, and epithelial‑Cadherin protein levels but decreased Cyclin D1 protein levels in OS cells. In addition, miR‑181b inhibition reduced OS cell proliferation and invasion. In contrast, p53 knockdown had the opposite effects on these proteins and OS cell proliferation and invasion. Above all, p53 knockdown significantly attenuated the effects of miR‑181b inhibition. Moreover, OS cell xenograft assays further confirmed the roles of the miR‑181b/p53 axis in OS growth. In conclusion, miR‑181b and p53 are negatively regulated by one another and therefore form a negative feedback axis that regulates the proliferation and invasion abilities of OS cells. Targeting miR‑181b to inhibit its abnormal upregulation might be a potent strategy for OS treatment.

View Figures

View References

1	Ma O, Cai WW, Zender L, Dayaram T, Shen J, Herron AJ, Lowe SW, Man TK, Lau CC and Donehower LA: MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 69:2559–2567. 2009. View Article : Google Scholar : PubMed/NCBI
2	Anderson ME: Update on survival in osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar
3	Duchman KR, Gao Y and Miller BJ: Prognostic factors for survival in patients with high-grade osteosarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 39:593–599. 2015. View Article : Google Scholar : PubMed/NCBI
4	Kedmi R, Veiga N, Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L, Leviatan-Ben-Arye S, Harlev M, et al: A modular platform for targeted RNAi therapeutics. Nat Nanotechnol. 13:214–219. 2018. View Article : Google Scholar : PubMed/NCBI
5	Shaikh AB, Li F, Li M, He B, He X, Chen G, Guo B, Li D, Jiang F, Dang L, et al: Present advances and future perspectives of molecular targeted therapy for osteosarcoma. Int J Mol Sci. 17:5062016. View Article : Google Scholar : PubMed/NCBI
6	Papiol S, Arias B, Barrantes-Vidal N, Guitart M, Salgado P, Catalán R and Fañanás L: Analysis of polymorphisms at the tumor suppressor gene p53 (TP53) in contributing to the risk for schizophrenia and its associated neurocognitive deficits. Neurosci Lett. 363:78–80. 2004. View Article : Google Scholar : PubMed/NCBI
7	Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan YC, Li H, Hu S, Weng Y and Yen Y: Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy. Hum Mutat. 35:575–584. 2014. View Article : Google Scholar : PubMed/NCBI
8	Xie Y, Zhu S, Song X, Sun X, Fan Y, Liu J, Zhong M, Yuan H, Zhang L, Billiar TR, et al: The tumor suppressor p53 limits ferroptosis by blocking DPP4 activity. Cell Rep. 20:1692–1704. 2017. View Article : Google Scholar : PubMed/NCBI
9	Bedi A and Mookerjee B: Biological significance and molecular mechanisms of p53-induced apoptosis. Apoptosis. 3:237–244. 1998. View Article : Google Scholar
10	Xie C, Wu B, Chen B, Shi Q, Guo J, Fan Z and Huang Y: Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2-p53 signaling. Onco Targets Ther. 9:4005–4013. 2016. View Article : Google Scholar : PubMed/NCBI
11	Zhou Y, Niu W, Luo Y, Li H, Xie Y, Wang H, Liu Y, Fan S, Li Z, Xiong W, et al: p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53. Cancer Sci. 110:939–949. 2019. View Article : Google Scholar : PubMed/NCBI
12	Chen Z, Guo J, Zhang K and Guo Y: TP53 mutations and survival in osteosarcoma patients: A meta-analysis of published data. Dis Markers. 2016:46395752016. View Article : Google Scholar : PubMed/NCBI
13	Luo Y, Deng Z and Chen J: Pivotal regulatory network and genes in osteosarcoma. Arch Med Sci. 9:569–575. 2013. View Article : Google Scholar : PubMed/NCBI
14	Zhao YX, Wang YS, Cai QQ, Wang JQ and Yao WT: Up-regulation of HDAC9 promotes cell proliferation through suppressing p53 transcription in osteosarcoma. Int J Clin Exp Med. 8:11818–11823. 2015.PubMed/NCBI
15	Wu J, Guo A, Li Q and Wang D: Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma. Future Oncol. 13:1883–1891. 2017. View Article : Google Scholar : PubMed/NCBI
16	Shukla GC, Singh J and Barik S: MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
17	Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB and Bartel DP: The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 310:1817–1821. 2005. View Article : Google Scholar : PubMed/NCBI
18	Pasquinelli AE, Hunter S and Bracht J: MicroRNAs: A developing story. Curr Opin Genet Dev. 15:200–205. 2005. View Article : Google Scholar : PubMed/NCBI
19	Jones KB, Salah Z, Del Mare S, Galasso M, Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et al: miRNA signatures associate with pathogenesis and progression of osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
20	Qin L, Chen Y, Niu Y, Chen W, Wang Q, Xiao S, Li A, Xie Y, Li J, Zhao X, et al: A deep investigation into the adipogenesis mechanism: Profile of microRNAs regulating adipogenesis by modulating the canonical Wnt/beta-catenin signaling pathway. BMC Genomics. 11:3202010. View Article : Google Scholar : PubMed/NCBI
21	Guo Y, Zi X, Koontz Z, Kim A, Xie J, Gorlick R, Holcombe RF and Hoang BH: Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res. 25:964–971. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zang X, Li Q, Wang W, Zhou Y, Chen S and Xiao T: miR-181a promotes the proliferation and metastasis of osteosarcoma cells by targeting RASSF1A. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 41:789–795. 2016.in Chinese; Abstract available in Chinese from the publisher. PubMed/NCBI
23	Zhu ZJ, Huang P, Chong YX, Kang LX, Huang X, Zhu ZX and Nie L: MicroRNA-181a promotes proliferation and inhibits apoptosis by suppressing CFIm25 in osteosarcoma. Mol Med Rep. 14:4271–4278. 2016. View Article : Google Scholar : PubMed/NCBI
24	Shao JL, Li ZZ, Wang L, Jiao GL, Zhou ZG and Sun GD: microRNA-181b promotes migration and invasion of osteosarcoma cells by targeting N-myc downstream regulated gene 2. Nan Fang Yi Ke Da Xue Xue Bao. 36:321–326. 2016.In Chinese. PubMed/NCBI
25	Wang W, Wang Z, Chen S, Zang X and Miao J: Interleukin-1β/nuclear factor-κB signaling promotes osteosarcoma cell growth through the microRNA-181b/phosphatase and tensin homolog axis. J Cell Biochem. 120:1763–1772. 2019. View Article : Google Scholar : PubMed/NCBI
26	Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ and Rao BN: Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: Imaging features. Cancer. 86:1602–1608. 1999. View Article : Google Scholar : PubMed/NCBI
27	McCarville MB, Kaste SC, Cain AM, Goloubeva O, Rao BN and Pratt CB: Prognostic factors and imaging patterns of recurrent pulmonary nodules after thoracotomy in children with osteosarcoma. Cancer. 91:1170–1176. 2001. View Article : Google Scholar : PubMed/NCBI
28	Nolan T, Hands RE and Bustin SA: Quantification of mRNA using real-time RT-PCR. Nat Protoc. 1:1559–1582. 2006. View Article : Google Scholar
29	Liu ZB, Wang JA and Lv RQ: Downregulation of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by PI3K-AKT signaling pathways and indicates good prognosis. Eur Rev Med Pharmacol Sci. 23:1418–1427. 2019.PubMed/NCBI
30	Zheng Y, Lv X, Wang X, Wang B, Shao X, Huang Y, Shi L, Chen Z, Huang J and Huang P: MiR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol Rep. 35:683–690. 2016. View Article : Google Scholar
31	Hong B, van den Heuvel AP, Prabhu VV, Zhang S and El-Deiry WS: Targeting tumor suppressor p53 for cancer therapy: Strategies, challenges and opportunities. Curr Drug Targets. 15:80–89. 2014. View Article : Google Scholar : PubMed/NCBI
32	Zhou J, Wu S, Chen Y, Zhao J, Zhang K, Wang J and Chen S: microRNA-143 is associated with the survival of ALDH1⁺CD133⁺ osteosarcoma cells and the chemoresistance of osteosarcoma. Exp Biol Med (Maywood). 240:867–875. 2015. View Article : Google Scholar
33	Mack DH, Vartikar J, Pipas JM and Laimins LA: Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature. 363:281–283. 1993. View Article : Google Scholar : PubMed/NCBI
34	Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ and Lowe SW: Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet. 37:1289–1295. 2005. View Article : Google Scholar : PubMed/NCBI
35	Mirza A, Wu Q, Wang L, McClanahan T, Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier P, et al: Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression. Oncogene. 22:3645–3654. 2003. View Article : Google Scholar : PubMed/NCBI
36	Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ and McDonnell TJ: Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem. 281:25134–25142. 2006. View Article : Google Scholar : PubMed/NCBI
37	He L, Yao H, Fan LH, Liu L, Qiu S, Li X, Gao JP and Hao CQ: MicroRNA-181b expression in prostate cancer tissues and its influence on the biological behavior of the prostate cancer cell line PC-3. Genet Mol Res. 12:1012–1021. 2013. View Article : Google Scholar : PubMed/NCBI
38	Yang L, Wang YL, Liu S, Zhang PP, Chen Z, Liu M and Tang H: miR-181b promotes cell proliferation and reduces apoptosis by repressing the expression of adenylyl cyclase 9 (AC9) in cervical cancer cells. FEBS Lett. 588:124–130. 2014. View Article : Google Scholar
39	Liu Y, Uzair-Ur-Rehman, Guo Y, Liang H, Cheng R, Yang F, Hong Y, Zhao C, Liu M, Yu M, et al: miR-181b functions as an oncomiR in colorectal cancer by targeting PDCD4. Protein Cell. 7:722–734. 2016. View Article : Google Scholar : PubMed/NCBI